--- title: "Dr Reddy's unveils oral diabetes drug Obeda for type 2 patients in India" type: "News" locale: "en" url: "https://longbridge.com/en/news/287073753.md" description: "Dr. Reddy’s Laboratories has launched Obeda, an oral semaglutide biosimilar for type 2 diabetes patients in India. This once-daily tablet aims to improve glycaemic control and follows the introduction of generic semaglutide injections. The CDSCO approved Obeda after a Phase III study showed its efficacy and safety comparable to the innovator drug. Available in three strengths, prices range from Rs 99 to Rs 225 per tablet. CEO M V Ramana emphasized the commitment to quality and supply reliability for diabetes care in India." datetime: "2026-05-20T05:18:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287073753.md) - [en](https://longbridge.com/en/news/287073753.md) - [zh-HK](https://longbridge.com/zh-HK/news/287073753.md) --- # Dr Reddy's unveils oral diabetes drug Obeda for type 2 patients in India Dr. Reddy’s Laboratories has announced the commercial launch of its oral semaglutide biosimilar under the brand name Obeda in India. The once-daily prescription tablet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults living with type 2 diabetes mellitus. The launch follows the company’s recent introduction of generic semaglutide injections in India and Canada, expanding its portfolio of glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapies. According to data cited from the ICMR-INDIAB study, India faces a significant metabolic disease burden, with more than 101 million adults diagnosed with diabetes, an 11.4 per cent prevalence rate, and approximately 136 million individuals classified as prediabetic. The Central Drugs Standard Control Organisation (CDSCO) granted marketing approval for Obeda following a review of data from a Phase III clinical study conducted in India. The trial enrolled 288 participants with type 2 diabetes. According to the company’s regulatory filing, the clinical study demonstrated non-inferior efficacy and a comparable safety profile to the innovator oral drug. The trial measured parameters including fasting and post-prandial plasma glucose, weight reduction, and the proportion of participants achieving an HbA1c level below 7 per cent at 12 and 24 weeks. Additionally, the study reported that no anti-drug antibodies were detected, indicating an immunogenicity profile comparable to the reference product. Obeda is formulated using a recombinant DNA (rDNA)-origin active pharmaceutical ingredient (API), developed and manufactured in-house by Dr. Reddy’s. The medication is available in three distinct strengths to allow flexible dosing, with pricing structured by dosage. The lowest strength, 3 mg, is priced at Rs 99 per tablet. The mid-range 7 mg dose is available at Rs 135 per tablet, while the highest strength of 14 mg is priced at Rs 225 per tablet. “The launch of our oral semaglutide for patients with diabetes marks an important step in our journey to broaden access to advanced diabetes care,” said M V Ramana, chief executive officer, Global Generics, at Dr. Reddy’s. “As the product is developed and formulated in-house, we are committed to reliable supply and consistent quality for patients in India.” The company stated that the in-house manufacturing structure is designed to secure supply-chain reliability for the chronic metabolic disease market in India and potentially other emerging regions. As a prescription-only medication, patients are advised to consult medical professionals regarding treatment regimens. ### Related Stocks - [RDY.US](https://longbridge.com/en/quote/RDY.US.md) ## Related News & Research - [Dr Reddy's Laboratories launches generic Semaglutide injection in Canada](https://longbridge.com/en/news/286635919.md) - [Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push](https://longbridge.com/en/news/286652907.md) - [Biosimilars could surpass generics in US mkt by early 2030s: Dr Reddy's CEO](https://longbridge.com/en/news/286680069.md) - [Dr. Reddy’s posts audio of March-quarter 2026 earnings call for investors](https://longbridge.com/en/news/286145430.md) - [BUZZ-PREVIEW-'Challenging Q4' for Indian pharma firm Dr Reddy's, analysts say](https://longbridge.com/en/news/286037312.md)